New treatment options for vascular dementia

Aging Health

Volumn 3, Issue 2, 2007, Pages 209-222

  Moretti, Rita ^a   Torre, Paola ^a   Antonello, Rodolfo M ^a   Vilotti, Cristina ^a   Pizzolato, Gilberto ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Dementia; Subcortical; Therapy; Vascular

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ACETYLCHOLINE; ACETYLSALICYLIC ACID; ALKALOID DERIVATIVE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ATYPICAL ANTIPSYCHOTIC AGENT; BAMBUTEROL; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CHOLINESTERASE INHIBITOR; CYPROTERONE ACETATE; DONEPEZIL; EPISTIGMINE; GALANTAMINE; GLUTAMATE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEMANTINE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BALANCE DISORDER; BEHAVIOR DISORDER; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DELUSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SELECTIVITY; FUNCTIONAL ASSESSMENT; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; MENTAL DISEASE; META ANALYSIS; MULTIINFARCT DEMENTIA; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PSYCHOSIS; REVIEW; RISK FACTOR; SOMNOLENCE; SYSTEMATIC REVIEW;

EID: 34247234673     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.3.2.209     Document Type: Review

References (128)

1. Hachinski V: Vascular dementia: a radical redefinition. Dementia 5, 130-132 (1994).
2. Roman GC, Tatemichi TK, Erkinjuntti T et al.: Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN international work group. Neurology 43, 250-260 (1993).
3. Erkinjuntti T. Vascular dementia: challenge of clinical diagnosis. Int. Psychogeriatr. 9, 77-83 (1997).
4. Pantoni L, Rossi R, Inzitari D et al.: Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J. Neurol. Sci. 175, 124-134 (2000).
5. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60(8), 1119-1122 (2003).
6. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 22(3), 312-318 (1991).
7. Wu CC, Mungas D, Petkov CI et al.: Brain structure and cognition in a community sample of elderly Latinos. Neurology 59(3), 383-391 (2002).
8. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348(13), 1215-1222 (2003).
9. Chui HC: Dementia. A review emphasizing clinico-pathologic correlation and brain-behaviour relationships. Arch. Neurol. 46(7), 806-814 (1989).
10. Skoog I, Nilsson L, Palmertz B et al.: A population-based study of dementia in 85-year olds. N. Engl. J. Med. 328, 153-158 (1993).
11. McKeith IG, Dickson DW, Lowe J et al.: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12), 1863-1872 (2005).
12. O'Brien J, Chiu E, McKeith I, Ames D: Dementia with Lewy Bodies. Taylor & Francis, NY, USA (2005).
13. Chui HC, Gatz M: Cultural diversity in Alzheimer disease: the interface between biology, belief, and behavior. Alzheimer Dis. Assoc. Discord. 19, 250-255 (2005).
14. Rocca WA, Hofman A, Brayne C et al.: The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies. EURODEM-Prevalence Research Group. Ann. Neurol. 30, 817-824 (1991).
15. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88(9), 1337-1342 (1998).
16. Roman GC: Vascular dementia prevention: a risk factor analysis. Cerebrovasc. Dis. 20(Suppl. 2), 91-100 (2005).
17. Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA: The apolipoprotein E ε4 allele increases the odds of chronic cerebral infarction detected at autopsy in older persons. Stroke 36(5), 954-959 (2005).
18. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R: The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 58, 1175-1181 (2002).
19. Prince M, Cullen M, Mann A: Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology 44, 97-104 (1994).
20. Hofman A, Ott A, Breteler MM et al.: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349, 151-154 (1997).
21. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA: Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch. Neurol. 58, 1640-1646 (2001).
22. Forette F, Seux M, Staessen JA et al.: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352(9137), 1347-1351 (1998).
23. van Dijck EJ, Breteler M, Schmidt R et al.: The association between blood pressure, hypertension, and cerebral white matter lesions. Hypertension 44, 625-650 (2004).
24. Moroney JT, Tang MX, Berglund L et al.: Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 282, 254-260 (1999).
25. Reitz C, Tang MX, Luchsinger J, Mayeux R: Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 61, 705-714 (2004).
26. Ross GW, Petrovitch H, White LR et al.: Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology 53, 337-343 (1999).
27. Romas SN, Tang MX, Berglund L, Mayeux R: APOE genotype, plasma lipids, lipoproteins, and AD in elderly. Neurology 53, 517-521 (1999).
28. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 356(9242), 1627-1631 (2000).
29. Hartmann T: Cholesterol and Alzheimer's disease: statins, cholesterol depletion in APP processing and Abeta generation. Subcell. Biochem. 38, 365-380 (2005).
30. Wolozine B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443 (2000).
31. Rockwood K, Kirkland S, Hogan DB et al.: Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223-227 (2002).
32. Curb JD, Rodriguez BL, Abbott RD et al.: Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 52, 971-975 (1999).
33. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61, 661-666 (2004).
34. Leibson CL, Rocca WA, Hanson VA et al.: Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 145, 301-308 (1997).
35. Luchsinger JA, Tang MX, Shea S, Mayeux R: Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192 (2004).
36. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr: Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168 (1998).
37. Brenner DE, Kukull WA, van Belle G et al.: Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology 43, 293-300 (1993).
38. Ford AB, Mefrouche Z, Friedland RP, Debanne SM: Smoking and cognitive impairment: a population based study. J. Am. Geriatr. Soc. 44, 905-909 (1996).
39. Graves AB, van Duijn CM, Chandra V et al.: Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int. J. Epidemiol. 20(Suppl. 2), S48-S57 (1991).
40. Hebert LE, Scherr PA, Beckett LA et al.: Relation of smoking and alcohol consumption to incident Alzheimer's disease. Am. J. Epidemiol. 135, 347-355 (1992).
41. Ott A, Slooter AJ, Hofman A et al.: Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351, 1840-1843 (1998).
42. Galanis DJ, Petrovitch H. Launer LJ. Harris TB, Foley DJ, White LR: Smoking history in middle age and subsequent cognitive performance in elderly Japanese-American men. The Honolulu-Asia Aging Study. Am. J. Epidemiol. 145, 507-515 (1997).
43. Prince M, Lewis G, Bird A, Blizard R, Mann A: A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population. Psychol. Med. 26, 555-568 (1996).
44. Seshadri S, Beiser A, Selhub J et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl. J. Med. 346, 476-483 (2002).
45. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM: Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am. J. Epidemiol. 150, 283-289 (1999).
46. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 55, 1449-1455 (1998).
47. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 13, 235-239 (1998).
48. Chui H: Vascular dementia, a new beginning. Neurol. Clin. 18(4), 951-975 (2000).
49. Pantoni L, del Ser T, Soglian AG et al.: Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 36(3), 619-624 (2005).
50. Meyer JS, Rogers RL, McClintic K et al.: Randomized clinical trial of daily aspirin in multi-infarct dementia. A pilot study. J. Am. Geriatr. Soc. 37, 549-555 (1989).
51. Perry E, Ziabreva I, Perry R, Aarsland D, Ballard C: Absence of cholinergic deficits in "pure" vascular dementia. Neurology 64(1), 132-133 (2005).
52. Tomimoto H, Ohtani R, Ihara M: Absence of cholinergic deficits in "pure" vascular dementia. Neurology 65(1), 179 (2005).
53. Vasquez J, Purve MJ: The cholinergic pathway to cerebral blood vessels. I. Morphological studies. Pflugers Arch. 379, 157-163 (1979).
54. Vanhoutte PM: Endothelium and control of vascular function. State of the art. Hypertension 13, 658-667 (1989).
55. Saito H, Togashi H, Yoshiaka M et al.: Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 22, S257-S259 (1995).
56. Togashi H, Matsumoto M, Yoshioka M et al.: Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Behav. Lett. 166, 117-120 (1994).
57. Kimura S, Saito H, Minami M et al.: Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 153, 167-187 (2000).
58. Scremin OU, Li MG, Scremin AM, Jenden DJ: Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex. Brain Res. Bull. 42, 59-70 (1997).
59. Tohgi H, Abe T, Kimura M et al.: Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer type dementia. J. Neurol. Transm. 103, 1211-1220 (1996).
60. Szilagy AK, Nemeth A, Martini E, Lendvai B, Venter V: Serum and CSF cholinesterase activity in various kind of dementia. Eur. Arch. Psychiatry Neurol. Sci. 236, 309-311 (1987).
61. Sakurada T, Alufuzoff I, Winblad B, Nordberg A: Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Res. 521(1-2), 329-332 (1990).
62. Olsen CE, Poulsen HD, Lublin HK: Drug therapy of dementia in elderly patients. A review. Nord. J. Psychiatry 59(2), 71-77 (2005).
63. Bullock R: Cholinesterase inhibitors and vascular dementia: another string to their bow? CNS Drugs 18(2), 79-92 (2004).
64. Erkinjuntti T, Kurz A, Gauthier S et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359, 1283-1290 (2002).
65. Erkinjuntti T: Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine. Eur. J. Neurol. 9(5), 545 (2002).
66. Erkinjuntti T: Treatment options. The latest evidence with galantamine (Reminyl®). J. Neurol. Sci. 203-204, 125-130 (2002).
67. Wilkinson D, Doody R, Helme R et al.: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61(4), 479-486 (2003).
68. Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ: Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement. Geriatr. Cogn. Disord. 20(6), 338-344 (2005).
69. Malouf R, Birks J: Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev. CD004395 (2004).
70. Passmore AP, Bayer AJ, Steinhagen-Thiessen E: Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J. Neurol. Sci. 229-230, 141-146 (2005).
71. Craig D, Birks J: Galantamine for vascular cognitive impairment. Cochrane Database Syst. Rev. CD004746 (2006).
72. Albuquerque EX, Alkondon M, Pereira EF et al.: Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 280, 1117-1136 (1997).
73. Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drug Aging 18, 891-898 (2001).
74. Perry EK, Perry RH, Blessed G, Tomlinson BE: Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 4, 273-277 (1978).
75. Mesulam M, Guillozet A, Shaw P, Quinn B: Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol. Dis. 9, 88-93 (2002).
76. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O: Preservation of cholinergic systems in AChE knockouts and the role of BuChE in acetylcholine hydrolysis. Abstr. - Soc. Neurosci. 27, 2565 (2001).
77. Massoulie J, Bon S: The molecular forms of cholinesterase and acetylcholine in vertebrates. Ann. Rev. Neurosci. 37, 57-106 (1982).
78. Poirier J: Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int. J. Clin. Pract. Suppl. 127, 6-19 (2002).
79. Massoulie J, Pezzementi L, Bon S et al.: Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41, 31-91 (1993).
80. Inglis F: The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl. 127, 45-63 (2002).
81. Okamoto K, Tanaka M, Kondo S: Treatment of vascular dementia. Ann. NY Acad. Sci. 977, 507-512 (2002).
82. Vennerica A, Shanks MF, Staff RT et al.: Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 13, 83-87 (2002).
83. Sharma T, Kumari V, Mitterschiffthaler M et al.: Cognitive effects of rivastigmine in Alzheimer's disease: an fMRI study. Presented at: The American College of Neuropsychopharmacology, 40th Annual Meeting. Waikoloa, Hawaii, 9-13 December 2001 (Poster).
84. Adler G, Brassen S: Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology 43, 273-276 (2001).
85. Nordberg A, Darreh-Shori T, Svensson A, Guan Z: Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J. Neurol. Sci. 187(Suppl. 1), P0144 (2001).
86. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR: Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J. Neural Transm. 109(7-8), 1053-1065 (2006).
87. Moretti R, Torre P, Antonello RM, Cazzato G: Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow up. Eur. J. Neurol. 8, 361-362 (2001).
88. Moretti R, Torre P, Antonello, RM, Cazzato G: Therapy of vascular dementia: perspectives and milestones. Therapy 2(4), 649-658 (2005).
89. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Rivastigmine in subcortical vascular dementia. An open 22-month study. J. Neurol. Sci. 203-204, 141-146 (2002).
90. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am. J. Alzheimers Dis. Other Demen. 18(5), 265-272 (2003).
91. Moretti R, Torre P, Antonello RM, Bava A, Cazzato G: Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month comparative study. Int. J. Clin. Pract. 58(4), 346-353 (2004).
92. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G: Delirium in vascular dementia: cholinesterase inhibition as a possibile therapy. A controlled, open 24-month study in 246 patients. Am. J. Alzheimers Dis. Other Demen. 19(6), 333-339 (2004).
93. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D: Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52 week open-label study. Curr. Med. Res. Opin. 20(10), 1605-1612 (2004).
94. Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin. Therapeutics 26(7), 980-989 (2004).
95. Danysz W, Zajaczkowski W, Parsons CG: Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6, 455-474 (1995).
96. Parsons C, Danysz W, Quack G: Glutamate in CNS disorders as a target for a drug development: an update. Drugs News Perspect. 11(9), 523-569 (1998).
97. Rothman SM, Olney JW: Excitotoxicity and the NMDA receptor. Trends Neurosci. 10, 299-302 (1987).
98. Choi DW: Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 18, 58-60 (1995).
99. Lipton SA: Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx, 1 101-110 (2004).
100. Fischer PA, Jacobi P, Schneider E et al.: Effects of intravenous administration of memantine in Parkinsonian patients. Arzneimittelforschung 27(7), 1487-1489 (1977).
101. Ditzler K: Efficacy and tolerability of memantine in patients with dementia syndrome: a double-blind, placebo controlled trial. Arzneimittelforschung 41(8), 773-802 (1991).
102. Gortelmeyer R, Erbler H: Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebo-controlled study. Arzneimittelforschung 42(7), 904-913 (1992)
103. Pantev M, Ritter R, Gortelmeyer R: Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Zeitschrit Fur Gerontopsychologie Und Psychiatrie 6, 103-117 (1993).
104. Ambrozi L, Danielczyk W: Treatment of impaired cerebral function in psychogeriatric patients with memantine - results of a phase II double-blind study. Pharmacopsychiatry 21(3), 144-146 (1988).
105. Chen HS, Pellegrini JW, Aggarwal SK et al.: Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12, 4427-4436 (1992).
106. 2+ in hippocampal slices. Neuropharmacology 38(9), 1253-1259 (1999).
107. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300) Stroke 33, 1834-1839 (2002).
108. Wilcock G, Mobius HJ, Stoffler A, MMM 500 group: A double-blind, placebo-controlled multi centre study of memantine in mild to moderate vascular dementia (MMM500) Int. Clin. Psychopharmacol. 17, 297-305 (2002)
109. Ballard CG, Margallo-Lana M, Fossey J et al.: A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J. Clin. Psychiatry 62, 631-636 (2001).
110. Lyketsos CG, Steinebrg M, Tschanz JT: Mental and behavioural disturbances in dementia: findings from the Cache county Study on Memory in Aging. Am. J. Psychiatry 157, 708-714 (2000).
111. O'Donnell BF, Drachmen DA, Barnes HJ, Petersen Ke, Swearer JM, Lew RA: Incontinence and troublesome behaviors predict instituzionalization in dementia. J. Geriatr. Psychiatry Neurol. 5, 45-52 (1992).
112. Kaufer D: Treatment of behavioral symptoms in Alzheimer's desease. American Academy of Neurology, MN, USA 5TP001, 7-19 (2000).
113. Motsinger CD, Perron GA, Lacy TJ: Use of atypical antipsychotic drugs in patients with dementia. Am. Fam. Physician 67(11), 2335-2340 (2003).
114. Alexopoulos GS, Streim J, Carpenter D, Docherty JP: Expert Consensus Panel for using antipsychotic drugs in older patients: using antipsychotic agents in older patients. J. Clin. Psychiatry 65(S2), 5-99 (2004).
115. Brodaty H, Ames D, Snowdon J et al.: A randomized placebo-controlled trial of risperidone in the treatment of aggression, agitation and psychosis of dementia. J. Clin. Psychiatry 64(2), 134-143 (2003).
116. Wooltorton E: Olanzapine (Zyprexa®), increased incidence of cerebrovascular events in dementia trials. CMAJ 170(9), 1395 (2004).
117. de Deyn PP, Rabheru K, Rasmussen A et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53, 946-955 (1999).
118. Herrmann N, Mamdani M, Lanctôt KL: Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry 161, 1113-1115 (2004).
119. Mowat D: CSM warning on atypical psychotics and stroke may be detrimental for dementia. BMJ 328, 1262 (2004).
120. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G: Olanzapine as a possible treatment of BPSD in vascular dementia: risk of cerebrovascular events. J. Neurol. 252, 1186-1193 (2005).
121. Street J, Clark S, Gannon KS et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry 57(10), 968-976 (2000).
122. Kennedy JS, Zagar A, Bymaster F et al.: The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int. J. Geriatr. Psych. 16, S24-S32 (2001).
123. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A: Treatment of behaviour disorders specific to patients with Alzheimer disease, vascular dementia and parkinsonism: a 24-month follow-up with olanzapine. Am. J. Alzheimers Dis. Other Demen. 18(4), 205-214 (2003).
124. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A: Anxiety symptoms due to vascular dementia. Olanzapine as a possible treatment: an open study. Am. J. Alzheimers Dis. Other Demen. 19(2), 81-89 (2004).
125. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double-blind trial. J. Clin. Psychiatry 60, 107-115 (1999).
126. Suh GH, Shah A: Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int. Psychogeriatr. 17(3), 429-441 (2005).
127. Cho KO, La HO, Cho YJ, Sung KW, Kim SY: Minocycline attenuates white damage in a rat model of chronic cerebral hypoperfusion. J. Neurosci. Res. 83(2), 285-291 (2006).
128. Caparros-Lefebvre D, Dewailly D: Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia. Rev. Neurol. (Paris) 161(11), 1071-1078 (2005).